Concepedia

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Shaji Kumar, Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vânia Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim,

The Lancet Oncology · 2020 · 404 citations · 22 references

DOI

Concepts

References

22

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

, , +17

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

S. Vincent Rajkumar, Jean‐Luc Harousseau, Brian G.M. Durie et al. · Blood · 2011 · 1K citations · Full text

, , +13

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

, , +17

Multiple myeloma: review of 869 cases.

PubMed · 1975 · 547 citations

, , +12

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto et al. · Blood · 2017 · 527 citations · Full text

, , +11